Revasum : Investor presentation for FY21 results

For personal use only

FY21 Results Presentation

ASX:RVS

Rebecca Shooter-Dodd, President & CEO

1 March 2022

1

DISCLAIMER

For personal use only

This presentation has been prepared by Revasum, Inc. (ARBN: 629 268 533) (Revasum) and is for information purposes only. Each recipient of this presentation is deemed to have agreed to accept the qualifications, limitations and disclaimers set out below.

The information provided in this document is general and may not be suitable for the specific purposes of any user of this document. It is not financial advice or a recommendation to acquire Revasum securities (ASX: RVS). Revasum believes that the information in this document is correct (although not complete or comprehensive), but none of Revasum or its subsidiaries or their respective directors, officers, employees, advisers or representatives (Beneficiaries) make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information contained in this presentation, including any forecast or prospective information. Users of this document should conduct their own independent review, investigations and analysis of Revasum and of the information contained or referred to in this presentation and obtain independent professional advice as to whether an investment in Revasum is appropriate for them, having regard to their personal objectives, risk profile, financial situation and needs, before relying on this document as the basis for any investment decision. Users should also refer to Revasum's financial statements lodged with the ASX for the period to which this document relates.

Future performance - Forward looking statements, opinions and estimates provided in this presentation are based on assumptions and contingencies which are subject to change without notice, as are statements about market and industry trends, which are based on interpretations of current market conditions. Forward looking statements including projections, guidance on future earnings and estimates are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. An investment in Revasum securities is subject to investment and other known and unknown risks, some of which are beyond the control of Revasum. No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of Revasum's employees, its directors, employees or agents, nor any other person accepts any liability, including, without limitation, any liability arising out of fault or negligence, for any loss arising from the use of the information contained in this presentation. In particular, no representation or warranty, express or implied is given as to the accuracy, completeness or correctness, likelihood of achievement or reasonableness of any forecasts, prospects or returns contained in this Presentation nor is any obligation assumed to update such information. Such forecasts, prospects or returns are by their nature subject to significant uncertainties and contingencies. Before making an investment decision, you should consider, with or without the assistance of a financial adviser, whether an investment is appropriate in light of your particular investment needs, objectives and financial circumstances.

Non-IFRS financial measures

Revasum uses certain measures to manage and report on its business that are not recognised under Australian Accounting Standards or IFRS. These measures are collectively referred to in this document as 'non-IFRS financial measures' under Regulatory Guide 230 'Disclosing non-IFRS financial information' published by ASIC. Management uses these non-IFRS financial measures to evaluate the performance and profitability of the overall business. The principal non-IFRS financial measures that are referred to in this document is EBITDA. EBITDA is earnings before interest, tax, depreciation and amortisation and significant items. Management uses EBITDA to evaluate the operating performance of the business prior to the impact of significant items, the non-cash impact of depreciation and amortisation and interest and tax charges.

Although Revasum believes that these measures provide useful information about the financial performance of Revasum, they should be considered as supplements to the income statement measures that have been presented in accordance with the Australia Accounting Standards and IFRS and not as a replacement for them.

Financial Data

All dollar values are in US dollars (US$) unless otherwise presented.

2

For personal use only

AT A GLANCE

COMPANY OVERVIEW

80+	600+	100%
Patents for CMP,	Worldwide Active	R&D and Manufacturing
Grind & Polish	Tool Install Base	In the US
US$13.7M	70+	SiC
FY21 Total Revenue	Employees	Experts in SiC Processing

HIGHLIGHTS

US$8.6M	35.3%	6EZ
Total Confirmed	Gross Margin improvement	PO Received for 2 x 6EZs
Sales Order Backlog	(+3.5% margin YoY)	First Unit Shipped,
As of 25 February 2022		Installed & Accepted

STOCK SNAPSHOT*

ASX:RVS	A$91.6M
Stock Ticker	Market Capitalization

A$0.90

Stock Price 25 February '22

US$4.3M	US$25M-US$35M
Cash on balance sheet	Forecast FY22
further supported by	Total Revenue
growth capital facility	80% - 155% y/o/y Increase

*Stock information as of 25 February 2022	3

For personal use only

FULLY-AUTOMATEDSINGLE-WAFER GRINDING & POLISHING SOLUTIONS FOR SILICON CARBIDE

Revasum designs and manufactures capital equipment for substrate conditioning and device manufacturing in the global semiconductor industry with a strategic focus on the Silicon Carbide (SiC) Market and wafer sizes ≤200mm. The Company's manufacturing and R&D is based in San Luis Obispo, California, USA.

7AF-HMG

Silicon Carbide Grinder

6EZ

Silicon Carbide Polisher

4

For personal use only

FY21 Financial Results

5